Regulatory T Cell Induction With Combined Immune Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases like Parkinson's disease are ineffective in slowing disease progression due to insufficient induction and maintenance of immune tolerance, as the immune system mistakenly attacks self-antigens, and existing immunomodulatory agents like GM-CSF and VIP have short half-lives and limited clinical efficacy.
Innovation Solution
Administering a combination of immune modulators, such as GM-CSF and IL-2, either simultaneously or sequentially, to induce and enhance regulatory T cell (Treg) populations, thereby restoring immune tolerance and reducing neuroinflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If single immunomodulatory agents (GM-CSF or VIP) are administered, then Treg induction is achieved, but the half-life is short and clinical efficacy is limited
Solution Approach 1:
The patent combines multiple immunomodulatory agents (GM-CSF and VIP) into a single composition that is administered together. This merging of agents creates a synergistic effect where GM-CSF promotes Treg proliferation and VIP enhances Treg stability and function, thereby extending the effective duration of action and improving clinical efficacy compared to single agent administration
2Reliability
If adoptive transfer of Tregs is performed, then immunological homeostasis is restored initially, but endogenous Treg dysfunction cannot be overcome and disease progression continues
Solution Approach 1:
The patent administers immunomodulatory agents (GM-CSF and VIP) before or concurrent with adoptive Treg transfer to pre-condition the immune environment. This preliminary action ensures that the transferred Tregs receive appropriate cytokine support and signals that enhance their survival, proliferation, and functional persistence, thereby overcoming endogenous Treg dysfunction and sustaining clinical benefit
Solution Approach 2:
The immunomodulatory agents (GM-CSF and VIP) serve as intermediaries between the transferred Tregs and the host immune system. These agents mediate the interaction by providing necessary growth factors and survival signals that bridge the gap between exogenous Treg transfer and endogenous immune environment, enabling sustained Treg function and long-term immunological homeostasis
Data Source
AI summary
The present invention provides novel compositions and methods for inducing and/or activating regulatory T cells (Treg). Wherein a method of treating, inhibiting, and/or preventing a disease or disorder in a subject in need thereof, said method comprising administering at least two immune modulators to said subject, is disclosed.